The second-generation anti-HER2 Affibody molecules (code-named ABY-025) have high stability, diminished interaction with immunoglobulins, and picomolar affinity for HER2 as well as rapid pharmacokinetics with fast blood clearance, resulting in high tumour-to-background ratios shortly after injection [7–10]. Here, ERBB2 is linked to neoplasm.